Abstract Library

#3065 Intensive Personalized Program for Daily Living with Neuroendocrine Neoplasms as a Chronic Disease: Preliminary Results

Introduction: Introduction: Neuroendocrine neoplasms (NENs) are increasingly viewed as chronic diseases as a result of more effective treatments and procedures. As with any life changing events, patient and family transition to a new “normal” requires attitudinal adjustments. The Intensive Personalized Program for Daily Living with Neuroendocrine Neoplasms is a pilot program transitioning patients and their primary familial carer to a new “normal”.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rosenberg M

Authors: Rosenberg M, Whyand T, Grozinsky-Glasberg S,

Keywords: QoL, Quality of Life, NEN Dietitian, PRO, Patient Reported Outcomes,

#3023 The Major Role of Neuroendocrine Tumor (NET)-Specialist Nurse in Improving NET Patients Disease-related QoL - Preliminary Data

Introduction: There is increasing evidence regarding the key role of dedicated specialist nurses in the treatment of cancer patients. Nurse coordinators serves as an available, accessible and knowledgeable resource for both patient and patient's family, more than the general registered nurses. They know better how to control symptoms and work as team players with multiple care providers.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Tal I, Grozinsky-Glasberg S, Oleinikov K, Gross D, Rosenberg M,

Keywords: NET-specialist nurse, NET nurse coordinator,

#2820 Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma

Introduction: Esthesioneuroblastoma (ENB) is a rare malignancy with limited therapeutic options when unresectable or metastatic. The overexpression of cell-surface somatostatin receptors in ENB is a potential molecular target making it amenable to peptide receptor radionuclide therapy (PRRT). High-level evidence supporting PRRT has been published for unresectable gastroenteropancreatic neuroendocrine tumours; however, data is limited for PRRT efficacy for ENB.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Kamel Hasan O

Authors: Kamel Hasan O, Ravi Kumar A, Kong G, Grozinsky-Glasberg S, Hicks R,

Keywords: esthesioneuroblastoma, peptide receptor radionuclide therapy, lutetium-177 dotatate,

#2817 METNET: A Phase II Trial of Metformin in Patients with Well Differentiated Neuroendocrine Tumors

Introduction: Preclinical studies have suggested that metformin has antitumor effects, likely due to blockage of mTOR pathway through AMPK and decreased insulin levels. A retrospective study showed that metformin combined with everolimus to treat related hyperglycemia offered longer progression-free survival (PFS) in patients (pts) with pancreatic neuroendocrine tumors (NET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Glasberg J

Authors: Glasberg J, Talans A, Lopez R, Recchimuzzi D, Riechelmann R,

Keywords: neuroendocrine tumors, metformin, clinical trial,

#2182 Favourable Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Metastatic Rectal Neuroendocrine Neoplasia (NEN)

Introduction: Metastatic disease from rectal NEN are less common than other NEN origins, and carries a poor prognosis. Treatment evidence for such patients (pts) is lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kong G

Authors: Kong G, Grozinsky-Glasberg S, Akhurst T, Hofman M, Meirovitz A,

Keywords: PRRT, Lu-177, metastatic, Rectal, Neuroendocrine neoplasm,